When.com Web Search

  1. Ads

    related to: lenacapavir fda approval date chart

Search results

  1. Results From The WOW.Com Content Network
  2. Lenacapavir - Wikipedia

    en.wikipedia.org/wiki/Lenacapavir

    Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]

  3. U.S. FDA approves Gilead's long-acting HIV drug Sunlenca - AOL

    www.aol.com/lifestyle/u-fda-approves-gileads...

    Gilead's Sunlenca, whose common name is lenacapavir, is given once every six months as an injection, but will be in addition to the current treatment regimen of patients. ... U.S. FDA approves ...

  4. An injectable HIV-prevention drug is highly effective — but ...

    www.aol.com/news/injectable-hiv-prevention-drug...

    The pharma giant has already secured approval for the injectable drug in treating highly drug-resistant HIV. Lenacapavir’s current list price for use as HIV treatment is $3,450 per month.

  5. List of antiretroviral fixed-dose combinations - Wikipedia

    en.wikipedia.org/wiki/List_of_antiretroviral...

    Food and Drug Administration (FDA) approval date: European Medicines Agency (EMA) approval date: Health Canada approval date: Company: Single-tablet regimen? NRTIs / NtRTIs: NNRTI: INSTI: PI: PK enhancer: Combivir: lamivudine zidovudine: September 26, 1997 ViiV Healthcare: No Kaletra (developed countries) Aluvia (developing countries) lopinavir ...

  6. Gilead's long-acting HIV drug superior to daily pill ... - AOL

    www.aol.com/news/gileads-long-acting-hiv-drug...

    Abrahams estimates lenacapavir potential sales to be more than $1.7 billion in PrEP. Lenacapavir, branded as Sunlenca, gained U.S. approval in 2022 as a treatment for heavily pre-treated HIV patients.

  7. HIV capsid inhibition - Wikipedia

    en.wikipedia.org/wiki/HIV_capsid_inhibition

    In 2022, the capsid inhibitor Lenacapavir received approval from the European Medicines Agency, Health Canada, and the United States Food and Drug Administration as a first-in-class medication to treat HIV-1 infection.

  1. Ads

    related to: lenacapavir fda approval date chart